LON:GSK - GlaxoSmithKline Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started GBX 1,584.60 +24.60 (+1.58 %) (As of 08/15/2018 10:46 AM ET)Previous CloseGBX 1,560Today's RangeGBX 1,561.60 - GBX 1,58952-Week RangeGBX 1,235.20 - GBX 1,724.50Volume5.63 million shsAverage Volume9.12 million shsMarket Capitalization£65.63 billionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; and a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Receive GSK News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical SymbolLON:GSK CUSIPN/A Webwww.gsk.com Phone+44-20-80475000 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins9.36% Return on Equity348.10% Return on Assets4.98% Miscellaneous EmployeesN/A Outstanding Shares4,920,000,000Market Cap£65.63 billion GlaxoSmithKline (LON:GSK) Frequently Asked Questions What is GlaxoSmithKline's stock symbol? GlaxoSmithKline trades on the London Stock Exchange (LON) under the ticker symbol "GSK." How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline? GlaxoSmithKline announced a dividend on Wednesday, July 25th. Shareholders of record on Thursday, August 9th will be given a dividend of GBX 19 per share on Thursday, October 11th. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 9th. The official announcement can be viewed at this link. View GlaxoSmithKline's Dividend History. How were GlaxoSmithKline's earnings last quarter? GlaxoSmithKline plc (LON:GSK) announced its quarterly earnings results on Wednesday, April, 25th. The company reported $24.60 EPS for the quarter, beating the Zacks' consensus estimate of $24.30 by $0.30. GlaxoSmithKline had a return on equity of 348.10% and a net margin of 9.36%. View GlaxoSmithKline's Earnings History. What price target have analysts set for GSK? 23 equities research analysts have issued twelve-month target prices for GlaxoSmithKline's stock. Their forecasts range from GBX 41.74 to GBX 2,000. On average, they expect GlaxoSmithKline's stock price to reach GBX 1,525.08 in the next year. This suggests that the stock has a possible downside of 3.9%. View Analyst Price Targets for GlaxoSmithKline. What is the consensus analysts' recommendation for GlaxoSmithKline? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 13 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline. Who are some of GlaxoSmithKline's key competitors? Some companies that are related to GlaxoSmithKline include Sanofi (SAN), Bayer (BAYN), AstraZeneca (AZN), BEXIMCO PHARMAC/S GDR REGS (BXP), OTSUKA HOLDINGS/ADR (OTSKY), Hutchison China MediTech (HCM), Dechra Pharmaceuticals (DPH), Mayne Pharma Group (MYX), Vectura Group (VEC), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Sinclair Pharma (SPH), Pharmaxis (PXS) and NanoViricides (NNVC). Who are GlaxoSmithKline's key executives? GlaxoSmithKline's management team includes the folowing people: Ms. Emma Walmsley, CEO & Director (Age 48)Mr. Simon P. Dingemans, CFO & Exec. Director (Age 54)Mr. Jack Bailey, Pres of US PharmaceuticalsMs. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55) Has GlaxoSmithKline been receiving favorable news coverage? News articles about GSK stock have trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.09 on Accern's scale. They also gave news articles about the company an impact score of 44.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for GlaxoSmithKline. How do I buy shares of GlaxoSmithKline? Shares of GSK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is GlaxoSmithKline's stock price today? One share of GSK stock can currently be purchased for approximately GBX 1,587. How big of a company is GlaxoSmithKline? GlaxoSmithKline has a market capitalization of £65.63 billion. How can I contact GlaxoSmithKline? GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The company can be reached via phone at +44-20-80475000. MarketBeat Community Rating for GlaxoSmithKline (LON GSK)Community Ranking: 1.8 out of 5 ()Outperform Votes: 758 (Vote Outperform)Underperform Votes: 1,345 (Vote Underperform)Total Votes: 2,103MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/15/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?